Canine and feline atopic dermatitis and allergic skin diseases are among the most persistent, frustrating chronic conditions seen in companion-animal practice. For more than two decades, oral cyclosporine—most widely known under the pioneer brand name Atopica—has served as a foundational calcineurin-inhibitor immunomodulator. By selectively blocking T-cell activation and down-regulating the transcription of pro-inflammatory cytokines like interleukin-2 (IL-2), cyclosporine controls allergic pruritus while avoiding the systemic catabolic side effects of long-term glucocorticoids.

However, because cyclosporine is prescribed for months or years to manage non-curable allergic disease, pet owners and veterinary teams frequently search for post-marketing safety data to understand real-world adverse-event rates, how long gastrointestinal side effects last, the true incidence of gingival hyperplasia (gum overgrowth), and species-specific safety profiles between dogs and cats.

Across 21,560 unique U.S. adverse-event reports naming cyclosporine filed with the FDA Center for Veterinary Medicine (CVM), domestic canines represent 15,012 reports (69.6%) and felines represent 2,987 reports (13.9%), with the remainder spanning unclassified species or accidental human contact. In the single-agent canine cohort (4,440 reports where cyclosporine was the only active ingredient), the leading reported clinical signs are vomiting (1,495 reports), diarrhea (758), depression/lethargy (395), pruritus (314), anorexia (304), emesis (246), lack of efficacy for atopic dermatitis (186), elevated alkaline phosphatase (144), and gingival hyperplasia in 133 reports.

Across all canine cyclosporine reports in the database, gingival hyperplasia appears in 564 cases, confirming that gum enlargement is a real, measurable pharmacologic signal. Overall mortality in single-agent canine reports is remarkably low (115 died and 26 euthanized, representing roughly 3.2% combined), reflecting an immunomodulator used for dermatologic quality of life rather than critical organ failure. For cats, cyclosporine presents a distinct clinical profile, carrying labeled warnings regarding Toxoplasma gondii serostatus and immunosuppression.

How many cyclosporine adverse-event reports are there, and what leads them in dogs versus cats?

The openFDA Animal and Veterinary Drug Adverse Event reporting system compiles mandatory post-marketing submissions from pharmaceutical sponsors alongside voluntary field reports from clinicians and pet owners. In the regulatory reporting snapshot through July 2026, 21,560 unique adverse-event reports list cyclosporine as an active substance.

Because cyclosporine is approved in distinct formulations for multiple veterinary indications—oral microemulsion capsules for dogs (Atopica NADA 141-218), oral solution for cats (Atopica for Cats NADA 141-329), and ophthalmic ointment for keratoconjunctivitis sicca (Optimmune NADA 141-052)—the dataset reflects diverse patient populations.

For an in-depth review of labeled indications, dosing intervals, and tapering schedules, see our companion guide on Atopica (cyclosporine) for dogs label and use.

┌──────────────────────────────────────────────────────────────────────────┐
│            CYCLOSPORINE FDA ADVERSE-EVENT ANNUAL REPORT TREND            │
├──────────────────────────────────────────────────────────────────────────┤
│ 2019: ██████████████ 511 reports                                         │
│ 2020: █████████████ 477 reports                                          │
│ 2021: ███████████ 421 reports                                            │
│ 2022: ███████████████ 540 reports                                        │
│ 2023: ██████████████ 521 reports                                         │
│ 2024: █████████████████ 606 reports                                      │
│ 2025: ███████████████████ 674 reports                                    │
│ 2026: ███ 123 reports (partial year through July 2026)                   │
└──────────────────────────────────────────────────────────────────────────┘

The modest upward trend in annual reporting from 2021 to 2025 aligns with expanded generic market penetration (such as Virbac's Cyclavance oral solution, approved under ANADA 200-692) and sustained long-term management of canine atopy.

Single-Agent Canine Adverse Events: Gastrointestinal Dominance and Gum Overgrowth

To isolate the adverse effects directly linked to cyclosporine from the confounding noise of concurrent antihistamines, antibiotics, or parasiticides, we analyzed the single-agent canine cohort of 4,440 reports:

Is gingival hyperplasia (gum overgrowth) really a cyclosporine side effect?

One of the most characteristic and clinically notable side effects of chronic cyclosporine administration is gingival hyperplasia—the benign enlargement and fibrous overgrowth of gingival tissue around the teeth.

┌──────────────────────────────────────────────────────────────────────────┐
│              CYCLOSPORINE GINGIVAL HYPERPLASIA SIGNAL                    │
├──────────────────────────────────────────────────────────────────────────┤
│ All Canine Cyclosporine Reports:        564 reports                      │
│ Single-Agent Canine Reports:            133 reports                      │
│ Typical Time of Onset:                  3 to 12 months of daily therapy  │
│ Histopathology:                         Fibrous hyperplasia with plasma  │
│                                         cell and lymphocyte infiltration │
│ Clinical Resolution:                    Regresses over 4–12 weeks upon   │
│                                         dose reduction or drug cessation │
└──────────────────────────────────────────────────────────────────────────┘

Pathophysiology and Clinical Management

Cyclosporine inhibits calcium-dependent intracellular signaling pathways not only in T-lymphocytes but also in gingival fibroblasts. It decreases the synthesis of matrix metalloproteinases (MMPs)—enzymes responsible for degrading extracellular collagen—while concurrently stimulating transforming growth factor-beta (TGF-β), leading to progressive collagen accumulation in the gingival stroma.

Key clinical considerations include:

1. Pre-existing Periodontal Disease: Dogs with poor oral hygiene and active plaque accumulation experience significantly higher rates of gingival hyperplasia. Plaque-induced local inflammation synergizes with cyclosporine's fibroblast stimulation.
2. Reversibility: Unlike drug-induced malignancies, cyclosporine-induced gingival hyperplasia is completely reversible. In mild cases, tapering the medication to alternate-day or twice-weekly maintenance often stabilizes or regresses the overgrowth. When the drug is discontinued, gingival contours typically return to normal within 1 to 3 months.
3. Medical Intervention (Azithromycin): For dogs that cannot discontinue cyclosporine without suffering severe allergic relapse, oral azithromycin or topical azithromycin toothpaste has been documented in peer-reviewed veterinary dentistry literature to inhibit cyclosporine-induced gingival fibroblast proliferation and reverse overgrowth without requiring surgical gingivectomy.

What do the lack-of-efficacy (INEFFECTIVE ATOPY CONTROL) reports mean?

In the single-agent canine cohort, 186 reports specifically document Ineffective Control of Atopy (therapeutic failure). While cyclosporine is highly effective, clinical trial literature and pharmacovigilance data demonstrate that roughly 20% to 30% of atopic dogs fail to achieve adequate clinical relief on cyclosporine monotherapy.

Several pharmacologic factors explain these reports:

1. Slow Onset of Action (The 4-Week Lag): Cyclosporine does not provide immediate itch relief. Unlike targeted therapies that block itch receptors within hours—such as the Janus kinase (JAK) inhibitor discussed in our Apoquel (oclacitinib) FDA adverse-event analysis—cyclosporine requires 3 to 6 weeks of continuous daily administration to achieve steady-state immunosuppression and clinical lesion regression. Frustrated owners who discontinue the drug after 10–14 days frequently report treatment failure.
2. Variable Bioavailability and Blood Levels: Cyclosporine is a lipophilic peptide with highly variable oral absorption. While microemulsified formulations (Atopica, Cyclavance) provide superior absorption compared to older non-microemulsified human formulations (Sandimmune), individual dogs exhibit up to a three-fold difference in peak blood concentrations.
3. Secondary Infections: Atopic dogs frequently suffer from secondary Staphylococcus pseudintermedius pyoderma or Malassezia dermatitis. Cyclosporine does not treat microbial infections; if bacterial folliculitis or yeast otitis is left untreated, the dog continues to scratch regardless of systemic T-cell inhibition. Performing a complete canine atopic dermatitis workup with skin cytology is essential before declaring treatment failure.

How do report tallies compare with Atopica's clinical trials and per-million-capsule rates?

To establish clinical perspective, post-marketing reporting counts should be evaluated alongside published prospective safety studies and manufacturer data.

In a seminal peer-reviewed multi-study meta-analysis published in the Veterinary Record (PMC3995266), researchers evaluated the long-term safety of oral microemulsified cyclosporine across thousands of treated dogs, calculating adverse-event incidence per million capsules sold:

This comparison highlights two crucial principles:

• High Relative Ranking vs. Low Absolute Incidence: While vomiting, diarrhea, and gingival hyperplasia are the most frequently submitted complaint terms to the FDA, prospective post-marketing epidemiological tracking proves their absolute incidence per administered dose is remarkably low (under 30 reports per million capsules).
• Transient Gastrointestinal Disturbance: In FDA approval trials, over 75% of vomiting episodes occurred during the first 14 days of therapy and resolved spontaneously without dose reduction as gastrointestinal adaptation occurred.

Compared to the widespread metabolic disturbances of chronic steroids—detailed in our corticosteroid side effects and why cyclosporine spares steroids guide—cyclosporine avoids polyuria, polydipsia, muscle wasting, and calcinosis cutis.

Are the infection and cancer warnings borne out in the reports?

The FDA-approved package insert for Atopica carries clear warnings regarding secondary infections and the potential development of malignant neoplasia (such as cutaneous lymphoma).

In our openFDA dataset:

• Cutaneous Papillomatosis: Viral warts appear in 8 single-agent canine reports (0.2%). These benign viral proliferations can occur when cellular immunity is suppressed, allowing latent canine papillomavirus to express. They generally regress once the cyclosporine dose is tapered. Their rarity in the report set is reassuring.
• Neoplasia / Lymphoma: Lymphoma was recorded in 15 single-agent canine reports (0.3%). Notably, the Atopica label contraindicates the drug in dogs with a history of neoplasia, and systemic T-cell inhibition can theoretically diminish tumor immunosurveillance. Even so, longitudinal clinical studies have not demonstrated a statistically significant increase in lymphoma rates among atopic dogs treated with therapeutic doses of cyclosporine compared to age-matched atopic control dogs, and the low report count here is consistent with that.
• Outcome Profile: In the single-agent canine dataset, 742 dogs were confirmed fully recovered, 322 were ongoing/managed, 115 died, and 26 were euthanized (~3.2% combined fatal outcomes). Fatalities occurred predominantly in elderly dogs with severe underlying systemic disease rather than direct cyclosporine toxicity.

What is different about cats, and what is the toxoplasmosis risk?

Feline patients represent 2,987 adverse-event reports in the openFDA dataset. Approved under NADA 141-329 (Atopica for Cats oral solution), cyclosporine is indicated for feline allergic dermatitis (non-flea, non-food hypersensitivity).

However, prescribing cyclosporine in cats requires unique clinical precautions:

┌──────────────────────────────────────────────────────────────────────────┐
│                   FELINE CYCLOSPORINE SAFETY MATRIX                      │
├──────────────────────────────────────────────────────────────────────────┤
│ 1. TOXOPLASMOSIS RISK:                                                   │
│    • Cyclosporine suppresses cell-mediated immunity against              │
│      Toxoplasma gondii.                                                  │
│    • Seronegative cats exposed to Toxoplasma oocysts during therapy      │
│      cannot mount an immune response, risking fatal systemic infection.  │
│    ──► LABEL RULE: Keep cats strictly indoors; DO NOT feed raw meat.     │
│        The Atopica for Cats label requires avoiding T. gondii            │
│        exposure. Some internists also baseline Toxoplasma serology.      │
├──────────────────────────────────────────────────────────────────────────┤
│ 2. RETROVIRAL SCREENING:                                                 │
│    • FeLV (Feline Leukemia) and FIV (Feline Immunodeficiency Virus)      │
│      compromise baseline T-cell function.                                │
│    ──► MANDATORY RULE: Perform FeLV/FIV test before prescribing.         │
│        Contraindicated in FeLV-positive or FIV-positive cats.            │
├──────────────────────────────────────────────────────────────────────────┤
│ 3. HEPATIC LIPIDOSIS VIGILANCE:                                          │
│    • Feline nausea and inappetence can trigger rapid hepatic lipidosis.  │
│    ──► ACTION: Monitor food intake daily; use antiemetics if nauseated.  │
└──────────────────────────────────────────────────────────────────────────┘

For ophthalmic applications of topical cyclosporine in companion animals, refer to our clinical review on dry eye (KCS) in dogs and Optimmune, and for an understanding of reporting mechanisms, consult how FDA animal drug adverse-event reporting works.

Practical Clinical Strategies: How to Mitigate Vomiting

For dog and cat owners struggling with initial gastrointestinal intolerance, veterinary pharmacologists recommend three proven clinical strategies:

1. Freezing the Capsules (Dogs): Freezing Atopica gelatin capsules in a household freezer does not alter drug bioavailability or chemical stability. Freezing delays gelatin shell dissolution until the capsule passes through the stomach into the duodenum, significantly reducing direct gastric irritation and nausea.
2. Administering with a Small Meal: While giving cyclosporine on an empty stomach (1 hour before or 2 hours after feeding) maximizes peak absorption, giving the medication with a small spoonful of food (such as canned food) reduces nausea and vomiting by more than 60% with only a minor, clinically acceptable decrease in bioavailability.
3. Short-Term Antiemetic Co-Administration: Prescribing a 5- to 7-day course of maropitant (Cerenia) or metoclopramide during the initial week of therapy prevents vomiting, maintains owner compliance, and allows the patient's gastrointestinal tract to adapt.

Frequently Asked Questions

Does freezing Atopica capsules really reduce vomiting, and does it hurt the medication?

Yes. Multiple clinical studies and manufacturer stability testing confirm that freezing Atopica capsules does not degrade the microemulsion or impair absorption. Freezing delays the capsule's dissolution until it enters the small intestine, bypassing gastric irritation and dramatically reducing nausea and vomiting in sensitive dogs.

How long do cyclosporine side effects last once I stop giving it?

Gastrointestinal side effects (vomiting, inappetence, loose stool) typically resolve within 24 to 48 hours after discontinuing cyclosporine. More complex tissue changes, such as gingival hyperplasia, resolve gradually over 4 to 12 weeks as oral fibroblasts normalize collagen turnover.

Why are there so many total reports for cyclosporine in the FDA database?

The 21,560 reports reflect the fact that cyclosporine has been FDA-approved for more than 20 years (since 2003) across multiple high-volume chronic indications (canine Atopica, feline Atopica, and ophthalmic Optimmune), combined with generic market expansions. Passive reporting numbers reflect cumulative multi-decade prescription volume rather than high acute drug danger.

Is there a generic Atopica, and do generics have a different safety profile?

Yes. Virbac manufactures Cyclavance (cyclosporine oral solution for dogs), approved under ANADA 200-692, alongside other bioequivalent generic formulations. Because FDA generic approval requires proving bioequivalence and pharmaceutical quality matching the pioneer NADA 141-218, the clinical efficacy and adverse-event profiles of approved generics are comparable to brand Atopica.

Sources

• FDA Center for Veterinary Medicine (CVM): Animal Drugs @ FDA — Atopica (cyclosporine capsules) NADA 141-218 Approval Data
• FDA Center for Veterinary Medicine (CVM): Atopica for Cats (cyclosporine oral solution) NADA 141-329 Approval Documentation
• openFDA API: Animal & Veterinary Drug Adverse Event Reporting Database
• Veterinary Record (PMC3995266): Steffan et al., Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis
• Today's Veterinary Practice: Oral Cyclosporine Use in Dogs: Indications, Pharmacology, and Adverse Effects
• Elanco Animal Health: Atopica (cyclosporine capsules, USP) Prescribing Information & Safety Profile
• PetMD Clinical Reference: Cyclosporine (Atopica) for Dogs & Cats: Uses, Dosage, and Side Effects